SRPT logo

SRPT
Sarepta Therapeutics Inc

26,750
Mkt Cap
$2.29B
Volume
4.62M
52W High
$44.14
52W Low
$10.42
PE Ratio
-2.58
SRPT Fundamentals
Price
$23.03
Prev Close
$21.79
Open
$22.12
50D MA
$19.68
Beta
1.24
Avg. Volume
2.45M
EPS (Annual)
-$7.13
P/B
2.01
Rev/Employee
$2.63M
$2,254.48
Loading...
Loading...
News
all
press releases
Sarepta Therapeutics Announces First Quarter 2026 Financial Results and Recent Corporate Developments
Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today reported financial results for the first quarter 2026. 'We entered 2026 with clear...
Business Wire·43m ago
News Placeholder
More News
News Placeholder
Are These 5 Biotech Stocks Set to Beat Q1 Earnings Estimates?
ANI Pharmaceuticals, Novavax and three other biotechs show strong Earnings ESP signals, hinting at potential Q1 earnings beat as sector results roll in.
Zacks·2d ago
News Placeholder
Sarepta Therapeutics (SRPT) Reports Next Week: Wall Street Expects Earnings Growth
Sarepta Therapeutics (SRPT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks·7d ago
News Placeholder
M&T Bank Corp Acquires Shares of 83,348 Sarepta Therapeutics, Inc. $SRPT
M&T Bank Corp purchased a new position in shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT - Free Report) during the fourth quarter, according to its most recent disclosure with the Securities and...
MarketBeat·7d ago
News Placeholder
Sarepta Therapeutics (SRPT) Projected to Post Quarterly Earnings on Wednesday
Sarepta Therapeutics (NASDAQ:SRPT) will be releasing its Q1 2026 earnings after the market closes on Wednesday, May 6. (View Earnings Report at...
MarketBeat·8d ago
News Placeholder
Ocugen Stock Outlook: Valuation, Cash Runway and Dilution Risk
Ocugen offers upside from a packed 2026 catalyst calendar, but cash runway limits and dilution risk keep the pre-commercial biotech outlook finely balanced.
Zacks·14d ago
News Placeholder
OCGN's Gene-Agnostic Strategy Could Reset Retinal Therapy
Ocugen's gene-agnostic therapy strategy targets broad retinal patient groups with one-time treatments, setting up major 2026-27 catalyst events.
Zacks·14d ago
News Placeholder
Sarepta Therapeutics to Announce First Quarter 2026 Financial Results
Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, will report first quarter 2026 financial results after the Nasdaq Global Market closes on Wednesday, May 6, 2026. Subsequently, at 4:30 p.m. E.T., the Company will host a conference call to discuss...
Business Wire·14d ago
News Placeholder
Sarepta Therapeutics, Inc. $SRPT Shares Purchased by Cwm LLC
Cwm LLC raised its position in shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT - Free Report) by 230.8% in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 240,536 shares of the biotechnology company's stock after purchasing...
MarketBeat·15d ago
News Placeholder
Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Receives Consensus Rating of "Hold" from Analysts
Shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT - Get Free Report) have earned an average rating of "Hold" from the twenty-eight research firms that are currently covering the firm, Marketbeat.com reports. Six research analysts have rated the stock with a sell recommendation, thirteen have assign...
MarketBeat·16d ago
<
1
2
...
>

Latest SRPT News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.